DrugPatentWatch Database Preview
Patent: 9,925,244
» See Plans and Pricing
Summary for Patent: 9,925,244
| Title: | Treatment of warts in non-immunosuppressed patients |
| Abstract: | A method for treating warts includes administering to a patient with warts a composition having an autologous, matched allogenic, donor tissue source of mixed, hematological, pleuripotent, ISPC derived or harvested or induced mesenchymal type stem cells and/or filgrastim, derivatives, bioequivalents, and pharmaceutically effective salts thereof. Patients include both non-chemotherapy or non-immunosuppressed patients, as well as chemotherapy or immunosupressed patients with warts of non-responsive cutaneous type. The treatment leads to resolution of warts and/or a change in their response to laser therapy or standard treatments previously shown not to be effective. |
| Inventor(s): | Chez; Michael (Granite City, CA) |
| Assignee: | |
| Application Number: | 15/045,294 |
| Patent Claims: | see list of patent claims |
Details for Patent 9,925,244
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Amgen | NEUPOGEN | filgrastim | SYRINGE | 103353 | 004 | 1991-02-20 | Start Trial | 2039-02-26 | RX | search | ||
| Amgen | NEUPOGEN | filgrastim | SYRINGE | 103353 | 003 | 1991-02-20 | Start Trial | 2039-02-26 | RX | search | ||
| Amgen | NEUPOGEN | filgrastim | VIAL | 103353 | 002 | 1991-02-20 | Start Trial | 2039-02-26 | RX | search | ||
| Amgen | NEUPOGEN | filgrastim | VIAL | 103353 | 001 | 1991-02-20 | Start Trial | 2039-02-26 | RX | search | ||
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
